Partial federal government shutdown
HCA does not anticipate any immediate impacts to our services or disruption to provider payments at this time. We will continue to monitor the situation and share updates if anything changes.
Glucose monitoring
Real-time continuous glucose monitoring (CGM) is advanced glucose monitoring technology that continuously measures interstitial glucose levels, displays the current blood glucose level as well as the direction and rate of change, and uses alarms and alerts to inform patients when blood glucose is exceeding or falling below specified thresholds.
Continuous glucose monitoring (CGM) was first reviewed by the HTA program in 2011.
In 2017, the HCA director selected glucose monitoring for rereview based on newly available published evidence that could change the original coverage determination.
Status: Decision complete
Why is CGM being reviewed?
CGM was proposed for rereview based on new evidence and expanded indications for use.
Primary criteria ranking
- Safety = Medium
- Efficacy = High
- Cost = High
Documentation
| Type | Materials |
|---|---|
| Assessment (2025) | |
| Assessment (2018) | |
| Assessment (2011) |
Assessment timeline (2025)
- Draft key questions published: September 3, 2024
- Public comment period: September 3 to 16, 2024
- Final key questions: October 2, 2024
- Draft report published: January 9, 2025
- Public comment period: January 9 to February 7, 2025
- Final report published: February 28, 2025
- HTCC public meeting: March 21, 2025
- Draft findings and decision published: March 28, 2025
- Public comment period: March 28 to April 11, 2025
- Final findings and decision published: June 23, 2025